BIOCOM for BIOCOM
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Jun 13, 2025 | $75,000 | Replaced |
| 1st Quarter - Report (this page) | Jun 13, 2025 | $75,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| MEGAN ELIZABETH KASTNER New | — |
Copyright/Patent/Trademark CPT
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| MEGAN ELIZABETH KASTNER New | — |
Taxation/Internal Revenue Code TAX
Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred Advocated to amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| MEGAN ELIZABETH KASTNER New | — |
Trade (domestic/foreign) TRD
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| MEGAN ELIZABETH KASTNER New | — |
Budget/Appropriations BUD
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
| MEGAN ELIZABETH KASTNER New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.